GLP-1 Receptor Agonists Transform Cardiometabolic Care, Offering Vascular Protection Beyond Glycemic Control

Traditional approaches to hypertension and cardiometabolic syndrome often focus on managing individual risk factors, which can fall short of addressing the underlying vascular-metabolic dysfunction. This gap necessitates therapies that can modify the fundamental biology driving these conditions. GLP-1 receptor agonists (GLP-1RAs) have emerged as a promising class, initially recognized for their roles in weight loss and glycemic control, but increasingly demonstrating broader benefits in cardiovascular and renal health. Understanding these extended mechanisms is crucial for optimizing their therapeutic application.

This comprehensive review integrates rapid clinical advancements with emerging mechanistic insights regarding GLP-1R agonists. The authors synthesize a wide array of clinical and experimental evidence to clarify which findings are well-established and which remain inferential concerning the cardiovascular and renal benefits of GLP-1RAs. The review identifies significant translational gaps, particularly in distinguishing direct GLP-1R signaling effects from secondary cardiometabolic changes, and in establishing precise cell type-resolved GLP-1R localization within human heart and kidney tissues. The methodology involved a critical analysis of existing literature to inform future research priorities.

GLP-1R agonists are transforming therapeutic strategies by shifting focus from mere risk factor control to modifying the vascular-metabolic biology underpinning hypertension and cardiometabolic syndrome. Beyond promoting weight loss and improved glycemic control, substantial clinical and experimental evidence highlights their beneficial effects on endothelial dysfunction, vascular inflammation, and leukocyte recruitment. They also positively influence atherosclerotic plaque composition and modulate crucial cardiorenal pathways involved in sodium regulation and neurohumoral balance, which are key processes in cardiometabolic-related hypertension and associated heart failure. The review emphasizes that while many benefits are established, further research is needed to differentiate direct GLP-1R signaling within cardiovascular/renal tissues from secondary systemic cardiometabolic improvements. This distinction is vital for a deeper understanding of their full therapeutic potential. > The integration of clinical success with mechanistic insights reveals GLP-1R agonists directly impact vascular-metabolic biology, offering benefits far beyond glucose lowering and weight management, including improved endothelial function and reduced vascular inflammation.